Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)

Trial Profile

Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Eflapegrastim (Primary) ; Cyclophosphamide; Docetaxel; Pegfilgrastim
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Acronyms RECOVER
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 According to a Spectrum Pharmaceuticals media release, this trial is expected to complete enrollment in Q1 2018.
    • 19 Jul 2017 Last checked against ClinicalTrials.gov record.
    • 12 Jul 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top